China Breast Cancer Diagnostics Market Size & Outlook
Related Markets
China breast cancer diagnostics market highlights
- The China breast cancer diagnostics market generated a revenue of USD 291.3 million in 2025 and is expected to reach USD 696.0 million by 2033.
- The China market is expected to grow at a CAGR of 11.7% from 2026 to 2033.
- In terms of segment, imaging was the largest revenue generating type in 2025.
- Blood Tests is the most lucrative type segment registering the fastest growth during the forecast period.
Breast cancer diagnostics market data book summary
| Market revenue in 2025 | USD 291.3 million |
| Market revenue in 2033 | USD 696.0 million |
| Growth rate | 11.7% (CAGR from 2026 to 2033) |
| Largest segment | Imaging |
| Fastest growing segment | Blood Tests |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Imaging, Biopsy, Genomic Tests, Blood Tests |
| Key market players worldwide | Hologic Inc, Genomic Health, BD, Danaher Corp, Koninklijke Philips NV, Qiagen NV, Thermo Fisher Scientific Inc, Argon Medical Devices, Myriad Genetics Inc, F. Hoffmann-La Roche Ltd. |
Other key industry trends
- In terms of revenue, China accounted for 5.0% of the global breast cancer diagnostics market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China breast cancer diagnostics market is projected to lead the regional market in terms of revenue in 2033.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 696.0 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Breast Cancer Diagnostics Market Scope
Breast Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Genomic Health | View profile | 501-1000 | Redwood City, California, United States, North America | http://www.genomichealth.com |
| F. Hoffmann-La Roche Ltd. | View profile | - | - | - |
| Argon Medical Devices | View profile | 1001-5000 | Plano, Texas, United States, North America | http://www.argonmedical.com/ |
| BD | View profile | 10001+ | Franklin Lakes, New Jersey, United States, North America | https://www.bd.com |
| Hologic Inc | View profile | 6990 | 250 Campus Drive, Marlborough, MA, United States, 01752 | http://www.hologic.com |
| Myriad Genetics Inc | View profile | 2700 | 320 Wakara Way, Salt Lake City, UT, United States, 84108 | https://www.myriad.com |
| Qiagen NV | View profile | 5900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | https://www.qiagen.com |
| Danaher Corp | View profile | 63000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | https://www.danaher.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Koninklijke Philips NV | View profile | 73712 | Philips Center, Amstelplein 2, Amsterdam, Netherlands, 1096 BC | https://www.philips.com |
China breast cancer diagnostics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to breast cancer diagnostics market will help companies and investors design strategic landscapes.
Imaging was the largest segment with a revenue share of 56.88% in 2025. Horizon Databook has segmented the China breast cancer diagnostics market based on imaging, biopsy, genomic tests, blood tests covering the revenue growth of each sub-segment from 2021 to 2033.
The market growth in China is being driven by various factors, including the increasing prevalence of breast cancer, advancements in breast imaging technology, and investments made by different organizations in breast cancer screening campaigns.
According to GLOBOCAN data, breast cancer in China is a significant health concern, with a notable increase in incidence and mortality rates over recent years. China reported 357,161 new breast cancer cases in 2022, making it one of the countries with the highest number of cases globally and this number is projected to reach 481,000 cases by 2040.
As breast cancer incidence rises, the demand for breast cancer diagnostics among patients in hospitals across China is expected to grow. This surge is also supported by the growing awareness of and access to breast cancer screening services, which are now being provided to more women in China.
Reasons to subscribe to China breast cancer diagnostics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China breast cancer diagnostics market databook
-
Our clientele includes a mix of breast cancer diagnostics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China breast cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into China breast cancer diagnostics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
China breast cancer diagnostics market size, by type, 2021-2033 (US$M)
China Breast Cancer Diagnostics Market Outlook Share, 2025 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
